---
document_datetime: 2023-09-21 18:32:54
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/mabthera-epar-procedural-steps-taken-authorisation_en.pdf
document_name: mabthera-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3625976
conversion_datetime: 2025-12-25 00:21:13.61912
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Roche Registration Ltd submitted on 27 February 1997, to the European Agency for the Evaluation of Medicinal Products (EMEA), an application to obtain Marketing Authorisation for the medicinal product Mabthera in accordance with the Centralised Procedure falling within the scope of Part A of the Annex to Council Regulation No (EC) 2309/93 of 22 July 1993.

The CPMP appointed the Rapporteur and the Co-Rapporteur were:

Rapporteur: H. Hovgaard

## Licensing status :

The product was not licensed in any country at the time of submission of the application.

Mabthera has been given a Marketing Authorisation in the following countries: USA on 26 November 1997, Switzerland on 27 November 1997

## 2. Steps taken for the assessment of the product

- The procedure started on 21 March 1997
- The Rapporteur's first assessment report was circulated to all CPMP Members on 4 June 1997. The Co-Rapporteur's first  assessment  report  was  circulated  to  all  CPMP  Members  on  2  June 1997.
- During the CPMP plenary meeting on 22 July 1997 the CPMP agreed on the consolidated list of questions  to  be  sent  to  the  company.  The  final  consolidated  list  of  questions  was  sent  to  the Company on 22 July 1997.
- The  company  submitted  the  responses  to  the  consolidated  list  of  questions  on  12  September 1997.
- The Rapporteur circulated the response assessment report on the company's responses to the list of  questions  to  all  CPMP  Members  on  28  October  1997.  The  Co-Rapporteur  circulated  the responses assessment report on the company's responses to the list of questions to all CPMP Members on 7 November 1997.
- The CPMP during its meeting on 19 November 1997 decided to convene an ad-hoc group of clinical experts in order to give answers to outstanding clinical issues.
- The ad-hoc group of clinical experts met on 7 January 1998 and the report from that meeting was circulated to the CPMP members.
- An oral presentation by the company on clinical issues took place during the CPMP meeting on 27 January 1998.
- The  CPMP,  during  its  meeting  on  27-28  January  1998  discussed  the  recommendations presented by the Rapporteur, Co-Rapporteur and the ad-hoc clinical experts group considering the  responses  and  additional  follow-up  data  provided  by  the  company . Amendments  were discussed to the Summary of Product Characteristics.
- The CPMP during its meeting of 27-28 January 1998, issued two positive opinions, one for each strength, for granting a marketing authorisation to Mabthera on 28 January 1998.
- The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 2 June 1998 .

Co-Rapporteur: Dr. W. F. van der Giesen